Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.72 |
| ▸ | EGFR | P00533 | 15/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033907 | 0.91 | ERBB2 (0.72) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL4382756 | 0.87 | EGFR (0.73) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL4028240 | 0.85 | ERBB2 (0.73) | ERBB2EGFR | |
| SCHEMBL4031196 | 0.85 | EGFR (0.70) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL4387806 | 0.85 | ERBB2 (0.76) | ERBB2EGFR | |
| SCHEMBL4383892 | 0.84 | EGFR (0.65) | ERBB2EGFR | |
| SCHEMBL4031651 | 0.83 | EGFR (0.92) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3815062 | 0.82 | EGFR (0.70) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL4029767 | 0.81 | ERBB2 (0.76) | ERBB2EGFRGAK | |
| SCHEMBL4036589 | 0.81 | EGFR (0.83) | ERBB2EGFRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | ERBB2 1/4885EGFR 4/4885GAK 178/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885GAK 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.